CYP2C9-mediated drug-drug interactions between bosentan and lopinavir/adagrasib

Bosentan, a dual endothelin receptor antagonist for pulmonary arterial hypertension (PAH), is vulnerable to drug-drug interactions (DDI) mediated by cytochrome P450 (CYP450) enzymes. We elucidated the effects of lopinavir and adagrasib on bosentan metabolism using rat liver microsomes (RLM), human liver microsomes (HLM) and recombinant human CYP2C9*1 (rCYP2C9), complemented by pharmacokinetics in rats and molecular dynamics (MD). In RLM, lopinavir and adagrasib inhibited bosentan metabolism with half-maximal inhibitory concentrations (IC 50 ) of 4.86 μM and 8.41 μM, respectively, displaying mixed and competitive inhibition mechanisms, respectively. In HLM, lopinavir and adagrasib exhibited noncompetitive and mixed inhibition mechanism with IC 50 of 27.75 and 15.16 μM, respectively. In rCYP2C9, both were noncompetitive inhibition mechanism with IC 50 of 34.55, 3.65 μM, respectively. In vivo, co-administration of lopinavir and adagrasib with bosentan, the AUC (0-t) and AUC (0-∞) of bosentan were increased by 107.2% and 176.6%, 106.8% and 176.1%, respectively, and t 1/2 was increased by 52.4% and 50.8%, respectively. For hydroxybosentan, AUC (0-t) and AUC (0-∞) were increased by 109.0% and 109.2% with adagrasib, accompanied by a 56.2% reduction in CL z/F under adagrasib co-administration. MD simulations suggested that lopinavir and adagrasib might inhibit CYP2C9-mediated bosentan metabolism by altering its positioning relative to the heme catalytic center. These findings underlined the potential DDI between bosentan and adagrasib or lopinavir, warranting cautious clinical co-administration.

Authors

Institutions

Publication Details

Journal
Cell Biology and Toxicology
Published
2026-11-16
DOI
https://doi.org/10.1007/s10565-026-10350-5
Primary Topic
Pharmacogenetics and Drug Metabolism
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

CYP2C9-mediated drug-drug interactions between bosentan and lopinavir/adagrasib

Ren-ai Xu, Haoxin Fu, Ruibin Li, Peiqi Wang et al.
Cell Biology and Toxicology
Pharmacogenetics and Drug Metabolism
article

CYP2C9-mediated drug-drug interactions between bosentan and lopinavir/adagrasib

Ren-ai Xu, Haoxin Fu, Ruibin Li, Peiqi Wang, Lu Cao, Jun Wu, Shiqi Jiang, Xiaoqun Xu
article en

Abstract

Bosentan, a dual endothelin receptor antagonist for pulmonary arterial hypertension (PAH), is vulnerable to drug-drug interactions (DDI) mediated by cytochrome P450 (CYP450) enzymes. We elucidated the effects of lopinavir and adagrasib on bosentan metabolism using rat liver microsomes (RLM), human liver microsomes (HLM) and recombinant human CYP2C9*1 (rCYP2C9), complemented by pharmacokinetics in rats and molecular dynamics (MD). In RLM, lopinavir and adagrasib inhibited bosentan metabolism with half-maximal inhibitory concentrations (IC 50 ) of 4.86 μM and 8.41 μM, respectively, displaying mixed and competitive inhibition mechanisms, respectively. In HLM, lopinavir and adagrasib exhibited noncompetitive and mixed inhibition mechanism with IC 50 of 27.75 and 15.16 μM, respectively. In rCYP2C9, both were noncompetitive inhibition mechanism with IC 50 of 34.55, 3.65 μM, respectively. In vivo, co-administration of lopinavir and adagrasib with bosentan, the AUC (0-t) and AUC (0-∞) of bosentan were increased by 107.2% and 176.6%, 106.8% and 176.1%, respectively, and t 1/2 was increased by 52.4% and 50.8%, respectively. For hydroxybosentan, AUC (0-t) and AUC (0-∞) were increased by 109.0% and 109.2% with adagrasib, accompanied by a 56.2% reduction in CL z/F under adagrasib co-administration. MD simulations suggested that lopinavir and adagrasib might inhibit CYP2C9-mediated bosentan metabolism by altering its positioning relative to the heme catalytic center. These findings underlined the potential DDI between bosentan and adagrasib or lopinavir, warranting cautious clinical co-administration.

Cell Biology and Toxicology
First Affiliated Hospital of Wenzhou Medical University (CN)
Good health and well-being
Pharmacogenetics and Drug Metabolism
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon